Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis

 

 Buy Article Permissions and Reprints

Summary

Kallikrein-related peptidases, a subgroup of the serine protease enzyme family, are considered to be important prognostic biomarkers in cancer. In this study we sought to determine the prognostic value of kallikrein-related peptidase 8 (KLK8,hK8,KLK-8) in ovarian cancer using a novel method of compartmentalised in situ protein analysis. A tissue array composed of 150 advanced stage ovarian cancers, uniformly treated with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For the evaluation of kallikrein-related peptidase 8 protein expression, we used an immunofluorescence-based method of automated in situ quantitative protein analysis (AQUA). Mean follow-up time of the cohort was 34.35 months. One hundred twenty-six of 150 cases had sufficient tissue for AQUA analysis. There were significant correlations between tumour mask KLK8 protein expression levels and clinicopathological variables, including grade (p=0.0011), residual disease (p=0.0063) and clinical response to chemotherapy(p=0.0346). In univariate survival analysis there was a significant correlation between KLK8 tumour mask expression and five years progression-free survival, meanwhile it was not associated with five-year overall survival (p =0.0694). Specifically, low KLK8 expression correlated with better outcome (top vs. bottom quartile, p=0.0319). In multivariate survival analysis, adjusting for well-characterised prognostic variables, tumour KLK8 expression level retained its prognostic significance for progression-free survival (95%CI: 0.341–1.027, p=0.045). The possibility that KLK8 may be a suitable candidate as a diagnostic and prognostic marker warrants further investigation.

^* These authors contributed equally to this paper.

• References

• 1 Jemal A, Tiwari RC, Murray T. et al. American Cancer Society. Cancer statistics 2004. CA Cancer J Clin 2004; 54: 8-29.
  CrossrefPubMedGoogle Scholar
• 2 Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-1538.
  CrossrefPubMedGoogle Scholar
• 3 Paliouras M, Diamandis EP. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 2006; 387: 643-652.
  PubMedGoogle Scholar
• 4 Yousef GM, Chang A, Scorilas A. et al. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000; 276: 125-133.
  CrossrefPubMedGoogle Scholar
• 5 Paliouras M, Diamandis EP. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res Treat 2007; 102: 7-18.
  CrossrefPubMedGoogle Scholar
• 6 Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
  CrossrefPubMedGoogle Scholar
• 7 Talieri M, Diamandis EP, Gourgiotis D. et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004; 91: 180-186.
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Shan SJ, Scorilas A, Katsaros D. et al. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem 2006; 52: 1879-1886.
  CrossrefPubMedGoogle Scholar
• 9 Diamandis EP, Scorilas A, Fracchioli S. et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003; 21: 1035-1043.
  CrossrefPubMedGoogle Scholar
• 10 Psyrri A, Kountourakis P, Scorilas A. et al. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression . Ann Oncol 2008; 19: 1271-1277.
  CrossrefPubMedGoogle Scholar
• 11 Yousef GM, Diamandis EP. Tissue kallikreins: new players in normal and abnormal cell growth?. Thromb Haemost 2003; 90: 7-16.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Yousef GM, Polymeris ME, Yacoub GM. et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003; 63: 2223-2227.
  PubMedGoogle Scholar
• 13 Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis . Cancer 1997; 80: 1529-1537.
  CrossrefPubMedGoogle Scholar
• 14 Diamandis EP, Yousef GM. Human tissue kallikreins: A family of new cancer biomarkers. Clin Chem 2002; 48: 1198-1205.
  PubMedGoogle Scholar
• 15 Camp RL, Chung GG, Rimm DL. Automated sub-cellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 1323-1327.
  CrossrefPubMedGoogle Scholar
• 16 World Health Organization.. WHO Handbook for Reporting Results of Cancer Treatment16–21 GW: WHO Handbook for Reporting Results of Cancer Treatment. Geneva. 1979 16-21.
  PubMedGoogle Scholar
• 17 Rimm DL, Camp RL, Charette LA. et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001; 7: 24-31.
  PubMedGoogle Scholar
• 18 Psyrri A, Kountourakis P, Yu Z. et al. Analysis of p53 Protein Expression Levels on Ovarian Cancer Tissue Microarray using Automated Quantitative Analysis (AQUA) elucidates Prognostic Patient Subsets . Ann Oncol 2007; 18: 709-715.
  PubMedGoogle Scholar
• 19 Komatsu N, Saijoh K, Toyama T. et al. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases . Br J Dermatol 2005; 153: 274-281.
  CrossrefPubMedGoogle Scholar
• 20 Dorn J, Schmitt M, Kates R. et al. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients . Clin Cancer Res 2007; 13: 1742-1748.
  CrossrefPubMedGoogle Scholar
• 21 Borgoño CA, Kishi T, Scorilas A. et al. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res 2006; 12: 1487-1493.
  CrossrefPubMedGoogle Scholar
• 22 Psyrri A, Kassar M, Yu Z. et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005; 11: 8637-8643.
  CrossrefPubMedGoogle Scholar
• 23 Suzuki J, Yoshida S, Chen Z. et al. Ontogeny of neuropsin in m RNA expression in the mouse brain . Neurosci Res 1995; 23: 345-351.
  CrossrefPubMedGoogle Scholar
• 24 Yoshida S, Shiosaka S. Plasticity-related serine proteases in the brain. Int J Mol Med 1999; 3: 405-409.
  PubMedGoogle Scholar
• 25 Borgoño CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004; 2: 257-280.
  PubMedGoogle Scholar
• 26 Kishi T, Grass L, Soosaipillai A. et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003; 63: 2771-2774.
  PubMedGoogle Scholar
• 27 Yousef GM, Kishi T, Diamandis EP. Role of kallikrein enzymes in the central nervous system. Clin Chim Acta 2003; 329: 1-8.
  CrossrefPubMedGoogle Scholar
• 28 Prezas P, Scorilas A, Yfanti C. et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem 2006; 387: 1607-1612.
  PubMedGoogle Scholar
• 29 Shigemasa K, Tian X, Gu L. et al. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep 2004; 11: 1153-1159.
  PubMedGoogle Scholar
• 30 Magklara A, Scorilas A, Katsaros D. et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001; 7: 806-811.
  PubMedGoogle Scholar
• 31 Sher YP, Chou CC, Chou RH. et al. Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res 2006; 66: 11763-11770.
  CrossrefPubMedGoogle Scholar
• 32 Rajapakse S, Ogiwara K, Takano N. et al. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. FEBS Lett 2005; 579: 6879-6884.
  CrossrefPubMedGoogle Scholar